Transmitted antiretroviral drug resistance mutations in newly diagnosed HIV‐1 positive patients in Turkey
Introduction The objective of this study was to determine the transmitted drug resistance mutations (TDRMs) in newly diagnosed HIV‐1 positive patients in Turkey. Materials and Methods The study was carried out between 2009 and 2014 and antiretroviral naïve 774 HIV‐1 infected patients from 19 Infecti...
Gespeichert in:
| Veröffentlicht in: | Journal of the International AIDS Society 2014-11, Vol.17 (4 Suppl 3), p.19750-n/a |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | n/a |
|---|---|
| container_issue | 4 Suppl 3 |
| container_start_page | 19750 |
| container_title | Journal of the International AIDS Society |
| container_volume | 17 |
| creator | Sayan, Murat Sargýn, Fatma Inan, Dilara Yýldýz Sevgi, Dilek Kocagül Celikbas, Aysel Yasar, Kadriye Kaptan, Figen Sayýn Kutlu, Selda Tasdelen Fýsgýn, Nuriye Inci, Ayse Ceran, Nurgül Karaoðlan, Ýlkay Cagatay, Atahan Kemal Celen, Mustafa Tekin Koruk, Suda Ceylan, Bahadýr Yýldýrmak, Taner Akalýn, Halis Korten, Volkan Willke, Ayse |
| description | Introduction
The objective of this study was to determine the transmitted drug resistance mutations (TDRMs) in newly diagnosed HIV‐1 positive patients in Turkey.
Materials and Methods
The study was carried out between 2009 and 2014 and antiretroviral naïve 774 HIV‐1 infected patients from 19 Infectious Diseases and Clinical Microbiology Departments in Turkey were included; gender: 664 (86%) male, median age: 37 (range; 1–77), median CD4+T‐cell: 360 (range; 1–1320) count/mm3, median HIV‐RNA load: 2.10+E6 (range; 4.2+E2–7.41+E8) IU/mL. HIV‐1 drug resistance mutations were detected by population based sequencing of the reverse transcriptase (codon 41–238) and protease (codon 1–99) domains of pol gene of HIV‐1, and analyzed according to the criteria by the World Health Organization 2009 list of surveillance drug resistance mutations [1].
Results
The patients had TDRMs to NRTIs (K65R, M184V), NNRTIs (K101E, K103N/S, G190A/E/S, Y181I/C, Y188H/L) and PIs (M46L, I54V, L76V, V82L/T, N83D, I84V, L90M). The prevalence of overall TDRMs was 6.7% (52/774). Resistance mutations were found to be 0.7% (6/774), 4.1% (32/774) and 2.1% (17/774) to NRTIs, NNRTIs and PIs drug groups, respectively. Three patients had NRTIs+NNRTs resistance mutations (M184V+K103N) as multi‐class drug resistance. However, thymidine analogue resistance mutations (TAMs) determined two distinct genotypic profiles in the HIV‐1 reverse transcriptase: TAM1: M41L, L210W and T215Y, and TAM2: D67N, K70R, K219E/Q, and T215F. The prevalence of TAM1 and TAM2 were 7.7% (60/774) and 4.3% (34/774), respectively.
Conclusions
The TDRMs prevalence of antiretroviral naïve HIV‐1 infected patients may be suggested current situation of Turkey. These long‐term and large‐scale results show that the resistance testing must be an integral part of the management of HIV infection in Turkey. |
| doi_str_mv | 10.7448/IAS.17.4.19750 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4225382</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A723606948</galeid><sourcerecordid>A723606948</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4720-274c62bf6c96626bcdc44c1de09cfac72c9a882acfadb39e7e7139b3ac79be3b3</originalsourceid><addsrcrecordid>eNqFkstuEzEUhkcIRC-wZYlGQqrYJNgejz3eIEUV0KBKLAhsLY_nzMTtjB1sT6rseIQ-I0-Ck5YqRRHIC1_Od36fW5a9wmjKKa3ezWdfp5hP6RQLXqIn2THmZTUhrCRP985H2UkIVwgxUlHxPDsiZSE4FeVxdr3wyobBxAhNrmw0HqJ3a-NVnzd-7HIPwYSorIZ8GKOKxtmQG5tbuOk3eWNUZ11Ivhfz779-3uJ85YKJZg35KrFg4w5ejP4aNi-yZ63qA7y830-zbx8_LM4vJpdfPs3PZ5cTTTlBE8KpZqRumRaMEVbrRlOqcQNI6FZpTrRQVUVUujR1IYADx4Woi2QSNRR1cZq9v9NdjfUAjU5RpHTkyptB-Y10ysjHFmuWsnNrSUkqTEWSwNt7Ae9-jBCiHEzQ0PfKghuDxCkszAosqoS--Qu9cqO3KT1ZIMZZgVKZ_0URUm1bgfa1OtWDNLZ1KTq9_VrOOCkYYoJuqckBqgMLKRVnoTXp-RE_PcCn1cBg9EGHsz2HJag-LoPrx13rDypr70Lw0D6UGCO5nU6ZplNiLqncTWdyeL3fmAf8zzgmgN4BNymmzX_k5Of5jOx0fwMxsvBy</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2289749098</pqid></control><display><type>article</type><title>Transmitted antiretroviral drug resistance mutations in newly diagnosed HIV‐1 positive patients in Turkey</title><source>Wiley-Blackwell Open Access Titles</source><source>DOAJ Directory of Open Access Journals</source><source>Wiley Online Library Journals Frontfile Complete</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><creator>Sayan, Murat ; Sargýn, Fatma ; Inan, Dilara ; Yýldýz Sevgi, Dilek ; Kocagül Celikbas, Aysel ; Yasar, Kadriye ; Kaptan, Figen ; Sayýn Kutlu, Selda ; Tasdelen Fýsgýn, Nuriye ; Inci, Ayse ; Ceran, Nurgül ; Karaoðlan, Ýlkay ; Cagatay, Atahan ; Kemal Celen, Mustafa ; Tekin Koruk, Suda ; Ceylan, Bahadýr ; Yýldýrmak, Taner ; Akalýn, Halis ; Korten, Volkan ; Willke, Ayse</creator><creatorcontrib>Sayan, Murat ; Sargýn, Fatma ; Inan, Dilara ; Yýldýz Sevgi, Dilek ; Kocagül Celikbas, Aysel ; Yasar, Kadriye ; Kaptan, Figen ; Sayýn Kutlu, Selda ; Tasdelen Fýsgýn, Nuriye ; Inci, Ayse ; Ceran, Nurgül ; Karaoðlan, Ýlkay ; Cagatay, Atahan ; Kemal Celen, Mustafa ; Tekin Koruk, Suda ; Ceylan, Bahadýr ; Yýldýrmak, Taner ; Akalýn, Halis ; Korten, Volkan ; Willke, Ayse</creatorcontrib><description>Introduction
The objective of this study was to determine the transmitted drug resistance mutations (TDRMs) in newly diagnosed HIV‐1 positive patients in Turkey.
Materials and Methods
The study was carried out between 2009 and 2014 and antiretroviral naïve 774 HIV‐1 infected patients from 19 Infectious Diseases and Clinical Microbiology Departments in Turkey were included; gender: 664 (86%) male, median age: 37 (range; 1–77), median CD4+T‐cell: 360 (range; 1–1320) count/mm3, median HIV‐RNA load: 2.10+E6 (range; 4.2+E2–7.41+E8) IU/mL. HIV‐1 drug resistance mutations were detected by population based sequencing of the reverse transcriptase (codon 41–238) and protease (codon 1–99) domains of pol gene of HIV‐1, and analyzed according to the criteria by the World Health Organization 2009 list of surveillance drug resistance mutations [1].
Results
The patients had TDRMs to NRTIs (K65R, M184V), NNRTIs (K101E, K103N/S, G190A/E/S, Y181I/C, Y188H/L) and PIs (M46L, I54V, L76V, V82L/T, N83D, I84V, L90M). The prevalence of overall TDRMs was 6.7% (52/774). Resistance mutations were found to be 0.7% (6/774), 4.1% (32/774) and 2.1% (17/774) to NRTIs, NNRTIs and PIs drug groups, respectively. Three patients had NRTIs+NNRTs resistance mutations (M184V+K103N) as multi‐class drug resistance. However, thymidine analogue resistance mutations (TAMs) determined two distinct genotypic profiles in the HIV‐1 reverse transcriptase: TAM1: M41L, L210W and T215Y, and TAM2: D67N, K70R, K219E/Q, and T215F. The prevalence of TAM1 and TAM2 were 7.7% (60/774) and 4.3% (34/774), respectively.
Conclusions
The TDRMs prevalence of antiretroviral naïve HIV‐1 infected patients may be suggested current situation of Turkey. These long‐term and large‐scale results show that the resistance testing must be an integral part of the management of HIV infection in Turkey.</description><identifier>ISSN: 1758-2652</identifier><identifier>EISSN: 1758-2652</identifier><identifier>DOI: 10.7448/IAS.17.4.19750</identifier><identifier>PMID: 25397495</identifier><language>eng</language><publisher>Switzerland: International AIDS Society</publisher><subject>Acquired immune deficiency syndrome ; AIDS ; Antiretroviral agents ; Antiretroviral drugs ; Diagnosis ; Drug resistance ; Gene mutations ; Genetic aspects ; GLP-1 receptor agonists ; HIV ; HIV infection ; Human immunodeficiency virus ; Infectious diseases ; Microbiology ; Mutation ; Statistics ; Viral drug resistance ; Virus research</subject><ispartof>Journal of the International AIDS Society, 2014-11, Vol.17 (4 Suppl 3), p.19750-n/a</ispartof><rights>2014 Sayan M et al; licensee International AIDS Society</rights><rights>COPYRIGHT 2014 John Wiley & Sons, Inc.</rights><rights>2014. This work is published under http://creativecommons.org/licenses/by/3.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2014 Sayan M et al; licensee International AIDS Society 2014</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4720-274c62bf6c96626bcdc44c1de09cfac72c9a882acfadb39e7e7139b3ac79be3b3</citedby><cites>FETCH-LOGICAL-c4720-274c62bf6c96626bcdc44c1de09cfac72c9a882acfadb39e7e7139b3ac79be3b3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4225382/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4225382/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,860,881,1411,11541,27901,27902,45550,45551,46027,46451,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25397495$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Sayan, Murat</creatorcontrib><creatorcontrib>Sargýn, Fatma</creatorcontrib><creatorcontrib>Inan, Dilara</creatorcontrib><creatorcontrib>Yýldýz Sevgi, Dilek</creatorcontrib><creatorcontrib>Kocagül Celikbas, Aysel</creatorcontrib><creatorcontrib>Yasar, Kadriye</creatorcontrib><creatorcontrib>Kaptan, Figen</creatorcontrib><creatorcontrib>Sayýn Kutlu, Selda</creatorcontrib><creatorcontrib>Tasdelen Fýsgýn, Nuriye</creatorcontrib><creatorcontrib>Inci, Ayse</creatorcontrib><creatorcontrib>Ceran, Nurgül</creatorcontrib><creatorcontrib>Karaoðlan, Ýlkay</creatorcontrib><creatorcontrib>Cagatay, Atahan</creatorcontrib><creatorcontrib>Kemal Celen, Mustafa</creatorcontrib><creatorcontrib>Tekin Koruk, Suda</creatorcontrib><creatorcontrib>Ceylan, Bahadýr</creatorcontrib><creatorcontrib>Yýldýrmak, Taner</creatorcontrib><creatorcontrib>Akalýn, Halis</creatorcontrib><creatorcontrib>Korten, Volkan</creatorcontrib><creatorcontrib>Willke, Ayse</creatorcontrib><title>Transmitted antiretroviral drug resistance mutations in newly diagnosed HIV‐1 positive patients in Turkey</title><title>Journal of the International AIDS Society</title><addtitle>J Int AIDS Soc</addtitle><description>Introduction
The objective of this study was to determine the transmitted drug resistance mutations (TDRMs) in newly diagnosed HIV‐1 positive patients in Turkey.
Materials and Methods
The study was carried out between 2009 and 2014 and antiretroviral naïve 774 HIV‐1 infected patients from 19 Infectious Diseases and Clinical Microbiology Departments in Turkey were included; gender: 664 (86%) male, median age: 37 (range; 1–77), median CD4+T‐cell: 360 (range; 1–1320) count/mm3, median HIV‐RNA load: 2.10+E6 (range; 4.2+E2–7.41+E8) IU/mL. HIV‐1 drug resistance mutations were detected by population based sequencing of the reverse transcriptase (codon 41–238) and protease (codon 1–99) domains of pol gene of HIV‐1, and analyzed according to the criteria by the World Health Organization 2009 list of surveillance drug resistance mutations [1].
Results
The patients had TDRMs to NRTIs (K65R, M184V), NNRTIs (K101E, K103N/S, G190A/E/S, Y181I/C, Y188H/L) and PIs (M46L, I54V, L76V, V82L/T, N83D, I84V, L90M). The prevalence of overall TDRMs was 6.7% (52/774). Resistance mutations were found to be 0.7% (6/774), 4.1% (32/774) and 2.1% (17/774) to NRTIs, NNRTIs and PIs drug groups, respectively. Three patients had NRTIs+NNRTs resistance mutations (M184V+K103N) as multi‐class drug resistance. However, thymidine analogue resistance mutations (TAMs) determined two distinct genotypic profiles in the HIV‐1 reverse transcriptase: TAM1: M41L, L210W and T215Y, and TAM2: D67N, K70R, K219E/Q, and T215F. The prevalence of TAM1 and TAM2 were 7.7% (60/774) and 4.3% (34/774), respectively.
Conclusions
The TDRMs prevalence of antiretroviral naïve HIV‐1 infected patients may be suggested current situation of Turkey. These long‐term and large‐scale results show that the resistance testing must be an integral part of the management of HIV infection in Turkey.</description><subject>Acquired immune deficiency syndrome</subject><subject>AIDS</subject><subject>Antiretroviral agents</subject><subject>Antiretroviral drugs</subject><subject>Diagnosis</subject><subject>Drug resistance</subject><subject>Gene mutations</subject><subject>Genetic aspects</subject><subject>GLP-1 receptor agonists</subject><subject>HIV</subject><subject>HIV infection</subject><subject>Human immunodeficiency virus</subject><subject>Infectious diseases</subject><subject>Microbiology</subject><subject>Mutation</subject><subject>Statistics</subject><subject>Viral drug resistance</subject><subject>Virus research</subject><issn>1758-2652</issn><issn>1758-2652</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>24P</sourceid><sourceid>BENPR</sourceid><recordid>eNqFkstuEzEUhkcIRC-wZYlGQqrYJNgejz3eIEUV0KBKLAhsLY_nzMTtjB1sT6rseIQ-I0-Ck5YqRRHIC1_Od36fW5a9wmjKKa3ezWdfp5hP6RQLXqIn2THmZTUhrCRP985H2UkIVwgxUlHxPDsiZSE4FeVxdr3wyobBxAhNrmw0HqJ3a-NVnzd-7HIPwYSorIZ8GKOKxtmQG5tbuOk3eWNUZ11Ivhfz779-3uJ85YKJZg35KrFg4w5ejP4aNi-yZ63qA7y830-zbx8_LM4vJpdfPs3PZ5cTTTlBE8KpZqRumRaMEVbrRlOqcQNI6FZpTrRQVUVUujR1IYADx4Woi2QSNRR1cZq9v9NdjfUAjU5RpHTkyptB-Y10ysjHFmuWsnNrSUkqTEWSwNt7Ae9-jBCiHEzQ0PfKghuDxCkszAosqoS--Qu9cqO3KT1ZIMZZgVKZ_0URUm1bgfa1OtWDNLZ1KTq9_VrOOCkYYoJuqckBqgMLKRVnoTXp-RE_PcCn1cBg9EGHsz2HJag-LoPrx13rDypr70Lw0D6UGCO5nU6ZplNiLqncTWdyeL3fmAf8zzgmgN4BNymmzX_k5Of5jOx0fwMxsvBy</recordid><startdate>201411</startdate><enddate>201411</enddate><creator>Sayan, Murat</creator><creator>Sargýn, Fatma</creator><creator>Inan, Dilara</creator><creator>Yýldýz Sevgi, Dilek</creator><creator>Kocagül Celikbas, Aysel</creator><creator>Yasar, Kadriye</creator><creator>Kaptan, Figen</creator><creator>Sayýn Kutlu, Selda</creator><creator>Tasdelen Fýsgýn, Nuriye</creator><creator>Inci, Ayse</creator><creator>Ceran, Nurgül</creator><creator>Karaoðlan, Ýlkay</creator><creator>Cagatay, Atahan</creator><creator>Kemal Celen, Mustafa</creator><creator>Tekin Koruk, Suda</creator><creator>Ceylan, Bahadýr</creator><creator>Yýldýrmak, Taner</creator><creator>Akalýn, Halis</creator><creator>Korten, Volkan</creator><creator>Willke, Ayse</creator><general>International AIDS Society</general><general>John Wiley & Sons, Inc</general><scope>24P</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>201411</creationdate><title>Transmitted antiretroviral drug resistance mutations in newly diagnosed HIV‐1 positive patients in Turkey</title><author>Sayan, Murat ; Sargýn, Fatma ; Inan, Dilara ; Yýldýz Sevgi, Dilek ; Kocagül Celikbas, Aysel ; Yasar, Kadriye ; Kaptan, Figen ; Sayýn Kutlu, Selda ; Tasdelen Fýsgýn, Nuriye ; Inci, Ayse ; Ceran, Nurgül ; Karaoðlan, Ýlkay ; Cagatay, Atahan ; Kemal Celen, Mustafa ; Tekin Koruk, Suda ; Ceylan, Bahadýr ; Yýldýrmak, Taner ; Akalýn, Halis ; Korten, Volkan ; Willke, Ayse</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4720-274c62bf6c96626bcdc44c1de09cfac72c9a882acfadb39e7e7139b3ac79be3b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Acquired immune deficiency syndrome</topic><topic>AIDS</topic><topic>Antiretroviral agents</topic><topic>Antiretroviral drugs</topic><topic>Diagnosis</topic><topic>Drug resistance</topic><topic>Gene mutations</topic><topic>Genetic aspects</topic><topic>GLP-1 receptor agonists</topic><topic>HIV</topic><topic>HIV infection</topic><topic>Human immunodeficiency virus</topic><topic>Infectious diseases</topic><topic>Microbiology</topic><topic>Mutation</topic><topic>Statistics</topic><topic>Viral drug resistance</topic><topic>Virus research</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Sayan, Murat</creatorcontrib><creatorcontrib>Sargýn, Fatma</creatorcontrib><creatorcontrib>Inan, Dilara</creatorcontrib><creatorcontrib>Yýldýz Sevgi, Dilek</creatorcontrib><creatorcontrib>Kocagül Celikbas, Aysel</creatorcontrib><creatorcontrib>Yasar, Kadriye</creatorcontrib><creatorcontrib>Kaptan, Figen</creatorcontrib><creatorcontrib>Sayýn Kutlu, Selda</creatorcontrib><creatorcontrib>Tasdelen Fýsgýn, Nuriye</creatorcontrib><creatorcontrib>Inci, Ayse</creatorcontrib><creatorcontrib>Ceran, Nurgül</creatorcontrib><creatorcontrib>Karaoðlan, Ýlkay</creatorcontrib><creatorcontrib>Cagatay, Atahan</creatorcontrib><creatorcontrib>Kemal Celen, Mustafa</creatorcontrib><creatorcontrib>Tekin Koruk, Suda</creatorcontrib><creatorcontrib>Ceylan, Bahadýr</creatorcontrib><creatorcontrib>Yýldýrmak, Taner</creatorcontrib><creatorcontrib>Akalýn, Halis</creatorcontrib><creatorcontrib>Korten, Volkan</creatorcontrib><creatorcontrib>Willke, Ayse</creatorcontrib><collection>Wiley-Blackwell Open Access Titles</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of the International AIDS Society</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Sayan, Murat</au><au>Sargýn, Fatma</au><au>Inan, Dilara</au><au>Yýldýz Sevgi, Dilek</au><au>Kocagül Celikbas, Aysel</au><au>Yasar, Kadriye</au><au>Kaptan, Figen</au><au>Sayýn Kutlu, Selda</au><au>Tasdelen Fýsgýn, Nuriye</au><au>Inci, Ayse</au><au>Ceran, Nurgül</au><au>Karaoðlan, Ýlkay</au><au>Cagatay, Atahan</au><au>Kemal Celen, Mustafa</au><au>Tekin Koruk, Suda</au><au>Ceylan, Bahadýr</au><au>Yýldýrmak, Taner</au><au>Akalýn, Halis</au><au>Korten, Volkan</au><au>Willke, Ayse</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Transmitted antiretroviral drug resistance mutations in newly diagnosed HIV‐1 positive patients in Turkey</atitle><jtitle>Journal of the International AIDS Society</jtitle><addtitle>J Int AIDS Soc</addtitle><date>2014-11</date><risdate>2014</risdate><volume>17</volume><issue>4 Suppl 3</issue><spage>19750</spage><epage>n/a</epage><pages>19750-n/a</pages><issn>1758-2652</issn><eissn>1758-2652</eissn><abstract>Introduction
The objective of this study was to determine the transmitted drug resistance mutations (TDRMs) in newly diagnosed HIV‐1 positive patients in Turkey.
Materials and Methods
The study was carried out between 2009 and 2014 and antiretroviral naïve 774 HIV‐1 infected patients from 19 Infectious Diseases and Clinical Microbiology Departments in Turkey were included; gender: 664 (86%) male, median age: 37 (range; 1–77), median CD4+T‐cell: 360 (range; 1–1320) count/mm3, median HIV‐RNA load: 2.10+E6 (range; 4.2+E2–7.41+E8) IU/mL. HIV‐1 drug resistance mutations were detected by population based sequencing of the reverse transcriptase (codon 41–238) and protease (codon 1–99) domains of pol gene of HIV‐1, and analyzed according to the criteria by the World Health Organization 2009 list of surveillance drug resistance mutations [1].
Results
The patients had TDRMs to NRTIs (K65R, M184V), NNRTIs (K101E, K103N/S, G190A/E/S, Y181I/C, Y188H/L) and PIs (M46L, I54V, L76V, V82L/T, N83D, I84V, L90M). The prevalence of overall TDRMs was 6.7% (52/774). Resistance mutations were found to be 0.7% (6/774), 4.1% (32/774) and 2.1% (17/774) to NRTIs, NNRTIs and PIs drug groups, respectively. Three patients had NRTIs+NNRTs resistance mutations (M184V+K103N) as multi‐class drug resistance. However, thymidine analogue resistance mutations (TAMs) determined two distinct genotypic profiles in the HIV‐1 reverse transcriptase: TAM1: M41L, L210W and T215Y, and TAM2: D67N, K70R, K219E/Q, and T215F. The prevalence of TAM1 and TAM2 were 7.7% (60/774) and 4.3% (34/774), respectively.
Conclusions
The TDRMs prevalence of antiretroviral naïve HIV‐1 infected patients may be suggested current situation of Turkey. These long‐term and large‐scale results show that the resistance testing must be an integral part of the management of HIV infection in Turkey.</abstract><cop>Switzerland</cop><pub>International AIDS Society</pub><pmid>25397495</pmid><doi>10.7448/IAS.17.4.19750</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1758-2652 |
| ispartof | Journal of the International AIDS Society, 2014-11, Vol.17 (4 Suppl 3), p.19750-n/a |
| issn | 1758-2652 1758-2652 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4225382 |
| source | Wiley-Blackwell Open Access Titles; DOAJ Directory of Open Access Journals; Wiley Online Library Journals Frontfile Complete; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central |
| subjects | Acquired immune deficiency syndrome AIDS Antiretroviral agents Antiretroviral drugs Diagnosis Drug resistance Gene mutations Genetic aspects GLP-1 receptor agonists HIV HIV infection Human immunodeficiency virus Infectious diseases Microbiology Mutation Statistics Viral drug resistance Virus research |
| title | Transmitted antiretroviral drug resistance mutations in newly diagnosed HIV‐1 positive patients in Turkey |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-30T19%3A17%3A01IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Transmitted%20antiretroviral%20drug%20resistance%20mutations%20in%20newly%20diagnosed%20HIV%E2%80%901%20positive%20patients%20in%20Turkey&rft.jtitle=Journal%20of%20the%20International%20AIDS%20Society&rft.au=Sayan,%20Murat&rft.date=2014-11&rft.volume=17&rft.issue=4%20Suppl%203&rft.spage=19750&rft.epage=n/a&rft.pages=19750-n/a&rft.issn=1758-2652&rft.eissn=1758-2652&rft_id=info:doi/10.7448/IAS.17.4.19750&rft_dat=%3Cgale_pubme%3EA723606948%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2289749098&rft_id=info:pmid/25397495&rft_galeid=A723606948&rfr_iscdi=true |